Identification and validation of N-acetylputrescine in combination with non-canonical clinical features as a Parkinson’s disease biomarker panel

作者：Kuan‐Wei Peng, Allison Klotz, Arcan Güven, Unnati Kapadnis, Shobha Ravipaty, Vladimir Tolstikov, Vijetha Vemulapalli, Leonardo O. Rodrigues, Hongyan Li, Mark D. Kellogg, Farah Kausar, Linda Rees, Rangaprasad Sarangarajan, Birgitt Schüle, William Langston, Paula P. Narain, Niven R. Narain, Michael A. Kiebish · 发表于：Scientific Reports · 年份：2024 · DOI：10.1038/s41598-024-60872-3 · 被引用次数：10 · 研究领域：Parkinson's Disease Mechanisms and Treatments、GABA and Rice Research、Alzheimer's disease research and treatments

Parkinson's disease is a progressive neurodegenerative disorder in which loss of dopaminergic neurons in the substantia nigra results in a clinically heterogeneous group with variable motor and non-motor symptoms with a degree of misdiagnosis. Only 3-25% of sporadic Parkinson's patients present with genetic abnormalities that could represent a risk factor, thus environmental, metabolic, and other unknown causes contribute to the pathogenesis of Parkinson's disease, which highlights the critical need for biomarkers. In the present study, we prospectively collected and analyzed plasma samples from 194 Parkinson's disease patients and 197 age-matched non-diseased controls. N-acetyl putrescine (NAP) in combination with sense of smell (B-SIT), depression/anxiety (HADS), and acting out dreams (RBD1Q) clinical measurements demonstrated combined diagnostic utility. NAP was increased by 28% in Parkinsons disease patients and exhibited an AUC of 0.72 as well as an OR of 4.79. The clinical and NAP panel demonstrated an area under the curve, AUC = 0.9 and an OR of 20.4. The assessed diagnostic panel demonstrates combinatorial utility in diagnosing Parkinson's disease, allowing for an integrated interpretation of disease pathophysiology and highlighting the use of multi-tiered panels in neurological disease diagnosis.